PE20081351A1 - QUINAZOLINE DERIVATIVES AS ANTI-CANCER AGENTS - Google Patents
QUINAZOLINE DERIVATIVES AS ANTI-CANCER AGENTSInfo
- Publication number
- PE20081351A1 PE20081351A1 PE2007001740A PE2007001740A PE20081351A1 PE 20081351 A1 PE20081351 A1 PE 20081351A1 PE 2007001740 A PE2007001740 A PE 2007001740A PE 2007001740 A PE2007001740 A PE 2007001740A PE 20081351 A1 PE20081351 A1 PE 20081351A1
- Authority
- PE
- Peru
- Prior art keywords
- cancer agents
- ethyl
- amino
- quinazoline derivatives
- quinazolin
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title abstract 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 abstract 1
- -1 AMINO, CARBAMOYL Chemical group 0.000 abstract 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical group O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 abstract 1
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
REFERIDA A UN DERIVADO DE QUINAZOLINA DE FORMULA (I), DONDE R1 ES HALOGENO, NITRO, CIANO, OH, TRIFLUOROMETOXI, ENTRE OTROS; n ES UN ENTERO DE 0 A 4; R2 ES HALOGENO, AMINO, CARBAMOILO, CARBOXI, ENTRE OTROS; m ES UN ENTERO DE 0 A 4. SON COMPUESTOS PREFERIDOS: N-[(1R)-1-(4-{[6-(4-METILPIRIDIN-3-IL)QUINAZOLIN-2-IL]AMINO}FENIL)ETIL]ACETAMIDA, 4-(6-BROMOQUINAZOLIN-2-ILAMINO)-N-(2-(DIMETILAMINO)ETIL)BENCENSULFONAMIDA, 3-METOXI-N-[(1R)-1-(4-{[6-(4-METILPIRIDIN-3-IL)QUINAZOLIN-2-IL]AMINO}FENIL)ETIL]PROPANAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCESO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA QUINASA B-RAF Y SON UTILES COMO AGENTES ANTICANCERIGENOSREFERRED TO A QUINAZOLINE DERIVATIVE OF FORMULA (I), WHERE R1 IS HALOGEN, NITRO, CYANE, OH, TRIFLUOROMETOXI, AMONG OTHERS; n IS AN INTEGER FROM 0 TO 4; R2 IS HALOGEN, AMINO, CARBAMOYL, CARBOXI, AMONG OTHERS; m IS AN INTEGER FROM 0 TO 4. PREFERRED COMPOUNDS ARE: N - [(1R) -1- (4 - {[6- (4-METHYLPYRIDIN-3-IL) QUINAZOLIN-2-IL] AMINO} PHENYL) ETHYL] ACETAMIDE, 4- (6-BROMOQUINAZOLIN-2-ILAMINO) -N- (2- (DIMETHYLAMINE) ETHYL) BENCENSULFONAMIDE, 3-METHOXY-N - [(1R) -1- (4 - {[6- (4-METHYLPYRIDIN -3-IL) QUINAZOLIN-2-IL] AMINO} PHENYL) ETHYL] PROPANAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCESS AND A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF PROTEIN KINASE B-RAF AND ARE USEFUL AS ANTI-CANCER AGENTS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86924106P | 2006-12-08 | 2006-12-08 | |
| US98573207P | 2007-11-06 | 2007-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081351A1 true PE20081351A1 (en) | 2008-11-26 |
Family
ID=39386079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001740A PE20081351A1 (en) | 2006-12-08 | 2007-12-07 | QUINAZOLINE DERIVATIVES AS ANTI-CANCER AGENTS |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR064208A1 (en) |
| CL (1) | CL2007003557A1 (en) |
| PE (1) | PE20081351A1 (en) |
| TW (1) | TW200829566A (en) |
| WO (1) | WO2008068507A2 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Fast Dissociting Dopamine 2 Receptor Antagonists |
| AU2007336893A1 (en) * | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for PDK1 inhibition |
| JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Fast -Dissociating Dopamine 2 Receptor Antagonists |
| CA2682671C (en) | 2007-04-23 | 2015-11-17 | Janssen Pharmaceutica N.V. | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists |
| PT2148873E (en) | 2007-04-23 | 2012-11-20 | Janssen Pharmaceutica Nv | 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists |
| KR101609218B1 (en) | 2008-07-31 | 2016-04-05 | 얀센 파마슈티카 엔.브이. | Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists |
| US20120041195A1 (en) | 2009-02-13 | 2012-02-16 | Fovea Pharmaceuticals | Heterocyclic compounds |
| TW201204723A (en) | 2010-06-22 | 2012-02-01 | Fovea Pharmaceuticals | Heterocyclic compounds, their preparation and their therapeutic application |
| WO2017001626A1 (en) | 2015-06-30 | 2017-01-05 | British Telecommunications Public Limited Company | Quality of service management in a network |
| US11198910B2 (en) | 2016-09-02 | 2021-12-14 | New England Biolabs, Inc. | Analysis of chromatin using a nicking enzyme |
| CN111170986A (en) * | 2018-11-13 | 2020-05-19 | 北京睿熙生物科技有限公司 | Inhibitors of bruton's tyrosine kinase |
| KR20210142154A (en) | 2019-03-21 | 2021-11-24 | 옹쎄오 | DBAIT molecules in combination with kinase inhibitors for the treatment of cancer |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2023138412A1 (en) * | 2022-01-20 | 2023-07-27 | Insilico Medicine Ip Limited | Fused pyrimidin-2-amine compounds as cdk20 inhibitors |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7691866B2 (en) * | 2003-10-16 | 2010-04-06 | Novartis Vaccines And Diagnostics, Inc. | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
-
2007
- 2007-12-06 TW TW096146631A patent/TW200829566A/en unknown
- 2007-12-07 WO PCT/GB2007/004697 patent/WO2008068507A2/en active Application Filing
- 2007-12-07 AR ARP070105508A patent/AR064208A1/en unknown
- 2007-12-07 PE PE2007001740A patent/PE20081351A1/en not_active Application Discontinuation
- 2007-12-07 CL CL200703557A patent/CL2007003557A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2007003557A1 (en) | 2008-08-01 |
| AR064208A1 (en) | 2009-03-18 |
| TW200829566A (en) | 2008-07-16 |
| WO2008068507A3 (en) | 2008-07-31 |
| WO2008068507A2 (en) | 2008-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081351A1 (en) | QUINAZOLINE DERIVATIVES AS ANTI-CANCER AGENTS | |
| PE20081393A1 (en) | QUINOLINE DERIVATIVES AS INHIBITORS OF CSF-1R | |
| PE20120814A1 (en) | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | |
| PE20090434A1 (en) | SULFONIL AMIDE DERIVATIVES AS KINASE INHIBITORS | |
| PE20141700A1 (en) | 2- (2,4,5-ANILINE SUBSTITUTED) PYRIMIDINE COMPOUNDS | |
| PE20090210A1 (en) | COMPOUNDS DERIVED FROM PYRAZOLO PYRIMIDINE AS INHIBITORS OF JAK QUINASE | |
| PE20090837A1 (en) | NEW CHEMICALS | |
| EA200970585A1 (en) | BENZAMIDE DERIVATIVES AS AGONISTS OF EP RECEPTORS | |
| PE20070593A1 (en) | PYRROLOPYRIMIDINE COMPOUNDS AS SYK INHIBITORS | |
| PE20070113A1 (en) | QUINOLINE AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AND TRKB TYROSINQUINASES | |
| IL177280A (en) | Crystalline monohydrate of a 2-aminothiazole-5-aromatic carboxamide, process for preparing same, pharmaceutical composition comprising same and use thereof for preparation of a medicament | |
| PE20061373A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING 'N- (2-CHLORO-6-METHYLPHENIL) -2 - [[6- [4- (2-HYDROXYETHYL) -1-PIPERAZINYL] -2-METHYL-4-PYRIMIDINYL] AMINO] -5- THIAZOLCARBOXAMIDE | |
| NZ593295A (en) | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinase inhibitor | |
| UY28885A1 (en) | 4-PHENYLAMINE-QUINAZOLIN-6-IL-AMIDAS CROSSED REFERENCE ON RELATED APPLICATION (S) | |
| PE20040647A1 (en) | TYROSINE KINE INHIBITORS | |
| PE20091623A1 (en) | 1H-PYRAZOLO [3,4-b] PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS | |
| EA200701705A1 (en) | ANTAGONISTS GLUCAGON RECEPTORS, OBTAINING AND THERAPEUTIC APPLICATION | |
| PE20081256A1 (en) | TRIAZALOPYRIDACINE AS A MODULATOR OF PROTEIN KINASE ACTIVITY | |
| PE20061394A1 (en) | METABOLITES OF N- (2-CHLORO-6-METHYLPHENYL) -2 - [[6- [4- (2-HYDROXYETHYL) -1-PIPERAZINYL] -2-METHYL-4-PYRIMIDINYL] AMINO] -5-THIAZOLCARBOXAMIDES | |
| UY29199A1 (en) | TIAZOL DERIVATIVES, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS | |
| NO20063620L (en) | Arylaniline derivatives as beta2 adrenergic receptor agonists | |
| EA201001769A1 (en) | DERIVATIVES OF QUINOLINES AND QUINOXALINS AS PROTEINTHYROSINKINASE INHIBITORS | |
| EA200870461A1 (en) | Lactam Derivatives of Cyclohexylimidazole as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 | |
| PE20121314A1 (en) | DERIVATIVES OF SUBSTITUTED 4-AMINOCICLOHEXANE | |
| DK1791830T3 (en) | Diaminotriazole compounds useful as protein kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |